Market Overview

UPDATE: Morgan Stanley Raises PT on Baxter International on Neutral Risk-Reward

Related BAX
Dan Loeb Sees Yellen In 'Hotel California,' Is Short More Stocks Than He Is Long
Earnings Scheduled For October 27, 2015
Biotechs Weaken, But These Names Have Bullish Charts (Investor's Business Daily)

In a report published Monday, Morgan Stanley analyst David R. Lewis reiterated an Overweight rating on Baxter International (NYSE: BAX), and raised the price target from $71.00 to $84.00.

In the report, Lewis noted, “We see a neutral risk-reward into Baxter's highly-anticipated PIII Alzheimer's data. We estimate the stock price currently includes roughly $3-5 in AD optionality, placing likely downside at 3-10% for a total failure (missed primary endpoints, missed subgroup analyses). Upside in the unlikely (p=5%) case of success on both primary endpoints could be $6-11, or 8-15%. Several intermediate cases of mixed results or suggestive subgroup analyses could drive less extreme outcomes and will likely punt investment implications until the presentation of full data results.”

Baxter International closed on Friday at $70.94.

Latest Ratings for BAX

Nov 2015Piper JaffrayAssumesOverweight
Oct 2015Leerink SwannMaintainsMarket Perform
Aug 2015BarclaysMaintainsOverweight

View More Analyst Ratings for BAX
View the Latest Analyst Ratings

Posted-In: Morgan StanleyAnalyst Color Price Target Analyst Ratings


Related Articles (BAX)

View Comments and Join the Discussion!

Get Benzinga's Newsletters